Calibration of Disease Simulation Model Using an Engineering Approach  by Vanni, Tazio et al.
Calibration of Disease Simulation Model Using an
Engineering Approachvhe_659 157
To the Editor—In a recent study, Kong et al. [1] addressed the
important question of how to calibrate complex models. Kong
et al. compared two parameter search algorithms to calibrate the
lung cancer policy microsimulation model. We believe that the
article is an important contribution to the literature for compar-
ing the performance of the two calibration algorithms and high-
lighting the importance of calibration in disease modeling and
the lack of standard calibration procedures.
The authors take the position that the only way to estimate
unobservable model parameters is using model calibration and
that the primary purpose of calibration is to estimate unobserv-
able natural history parameters (p. 521, paragraph 2). Never-
theless, unobserved parameters can be estimated using other
methods besides model calibration and, perhaps more impor-
tantly, the beneﬁts of model calibration go far beyond estimation
of unobserved natural history parameters.
Alternative methods to estimate unobservable parameters
include Parmigiani, who solved an integral equation for the
unobservable incidence rate of preclinical tumors that included
previously developed theories of the growth rate of breast tumors
[2,3]. Another commonly used approach is elicitation of expert
opinions [2]. The microsimulation screening analysis (MISCAN)
colorectal model was populated over the course of a 2-day expert
meeting at which all input parameters were deﬁned [4]. Expert
opinion elicitation can also be integrated with calibration
methods to deﬁne the ranges of allowable parameter values, as
Kong et al. raised as an issue of concern in the discussion of their
study [1].
Besides allowing the estimation of unobserved parameters,
model calibration is also a way to evaluate and adjust the con-
sistency of model structural and parameter assumptions [5,6].
Given that a model should be based on the best current scientiﬁc
understanding of the disease (that is likely to change over time),
and simplifying assumptions and input parameters from different
sources will have been used, it is sensible to explore how consis-
tent this combination of assumptions (the model) really is. This
can be done by comparing the model output to empirical data
(e.g., disease prevalence rates or mortality rates) and, if the model
does not provide a good ﬁt to the data, by exploring variation
(within a prior plausible bounds) in the structural or parameter
assumptions to identify combinations that provide a better ﬁt to
the data. Commonly, only parameters are varied to achieve an
improved ﬁt [2], but variation of other components including
health states and pathways (structural assumptions) can also be
explored during calibration within the known uncertainty asso-
ciated with these assumptions [7–9]. Another advantage of using
model calibration to estimate the parameters of the model is that
the estimation process will induce correlation between the
parameter estimates. This is particularly beneﬁcial given that it is
often difﬁcult to identify and establish correlation between
parameters in disease models [10].
The calibration of disease models is an important and active
area of methodological research and this article is a welcome
addition. The search for the parameter sets that minimize the
discrepancy between model output and multiple calibration
targets is just one area that should be explored in future research.
Others include the selection of the weights to be used in the
global goodness-of-ﬁt statistic, the methods used to assess good-
ness of ﬁt (least squares, chi-square, maximum likelihood, etc.),
and, perhaps of critical importance for economic evaluation
analysis, the methods used to integrate the results of model
calibration and economic parameters.—Tazio Vanni, MD, MSc,
Rosa Legood, PhD, Department of Public Health and Policy,
London School of Hygiene and Tropical Medicine, London, UK;
and Richard G. White, PhD, Department of Epidemiology and
Population Health, London School of Hygiene and Tropical
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